AN EXTENDED PHASE-II TRIAL OF IFOSFAMIDE PLUS MESNA IN MALIGNANT MESOTHELIOMA

Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna. Eligibility criteria included adequate performance status, hemogram and renal functions. Ifosfamide was given at 1.5 g/m2 in 200 ml of normal saline over 30 minutes by intravenous infusion on days 1 to 5 of each 21 day cycle. Mesna was given at 300 mg/m2 on each day of ifosfamide at 0,4 and 8 hours. Two patients were cancelled and one patient was ineligible. The most common toxicity was haematologic. More than 50% of the patients had at least one episode of severe or life threatening toxicity and 2 patients had lethal toxicity (1 renal and 1 pulmonary oedema attributed to treatment), and an additional 4 patients died while on study (2 of cardiac and 2 of cerebral vascular disease not considered directly related to treatment). Of the 40 eligible patients one was unevaluable for response, and one patient had a partial response lasting 6.3 months. Twenty four patients had a no change status with a median duration of 5 months. The median time to treatment failure for all eligible patients was 2.5 months. The median overall survival time (from registration) for all eligible patients was 6.9 months. In multi variable models, factors that predicted for a statistically significant poorer survival were age greater-than-or-equal-to 62, stage greater-than-or-equal-to 3, performance status poorer than 0 to 1 and prior surgery (i.e.: more than biopsy). The severe toxicity, documented in more than half of the patients, precludes any further dose escalation of ifosfamide in these patients. With only one. response among 39 evaluable patients, it is concluded, from this extended phase II trial, that ifosfamide does not have a worthwhile therapeutic effect in patients with malignant mesothelioma.